Matches in Wikidata for { <http://www.wikidata.org/entity/Q92490144> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- Q92490144 description "artículu científicu espublizáu n'agostu de 2019" @default.
- Q92490144 description "scientific article published on 07 August 2019" @default.
- Q92490144 description "wetenschappelijk artikel" @default.
- Q92490144 description "наукова стаття, опублікована 7 серпня 2019" @default.
- Q92490144 name "Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)" @default.
- Q92490144 name "Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)" @default.
- Q92490144 type Item @default.
- Q92490144 label "Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)" @default.
- Q92490144 label "Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)" @default.
- Q92490144 prefLabel "Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)" @default.
- Q92490144 prefLabel "Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)" @default.
- Q92490144 P1433 Q92490144-D2044D94-6A82-49D3-99F8-CD41E722ACE3 @default.
- Q92490144 P1476 Q92490144-B43CBE1A-956F-49E0-BDAA-7D30C5F8D1E2 @default.
- Q92490144 P2093 Q92490144-0396E964-343E-4219-AF39-7860369F8FF6 @default.
- Q92490144 P2093 Q92490144-03EC4573-BFA5-4C63-8F0D-963FF121928D @default.
- Q92490144 P2093 Q92490144-290E559A-C27C-4902-804B-B43B2FA6BEA9 @default.
- Q92490144 P2093 Q92490144-2EF8FED2-E160-4549-9085-300D282399A9 @default.
- Q92490144 P2093 Q92490144-3ED3A50A-AD7C-47D6-90B1-709C8F183ED6 @default.
- Q92490144 P2093 Q92490144-6BB068EB-3D86-4578-B7D8-0797A44F3B0E @default.
- Q92490144 P2093 Q92490144-6E5E94EC-738D-4D42-8985-6A4BF9F94EAF @default.
- Q92490144 P2093 Q92490144-6FD1F3AF-EA63-4465-9C6E-274E2D3C4F02 @default.
- Q92490144 P2093 Q92490144-7663477E-5A48-47B3-9218-604A0B3FD878 @default.
- Q92490144 P2093 Q92490144-82F51EBB-2AC9-45A9-8140-A75F9DE006CE @default.
- Q92490144 P2093 Q92490144-897A055E-F49E-4E57-AE7A-06552112D43F @default.
- Q92490144 P2093 Q92490144-913FF580-21E9-4011-8AE4-73C4A197DE89 @default.
- Q92490144 P2093 Q92490144-9490154F-6170-426D-90C4-6AFA5DE4AB8F @default.
- Q92490144 P2093 Q92490144-A1925A23-8AD3-458A-B28F-01BAA9404D80 @default.
- Q92490144 P2093 Q92490144-B8604ABC-0318-4644-AC73-128D03FF99CF @default.
- Q92490144 P2093 Q92490144-CCAC215D-4BFF-49B7-A9FA-EA9B949401E1 @default.
- Q92490144 P2093 Q92490144-D6A9C849-6398-43B1-953E-5A828F70F6B8 @default.
- Q92490144 P2093 Q92490144-F4AF0726-C680-4074-96A3-1722E43B92D2 @default.
- Q92490144 P2093 Q92490144-FD5A753C-77F0-4681-90CF-BFE4588C114E @default.
- Q92490144 P304 Q92490144-EBBA6706-F91D-4C79-8853-DAC053A72E68 @default.
- Q92490144 P31 Q92490144-209F5D2F-4185-4A63-9293-03F75BDE76C4 @default.
- Q92490144 P356 Q92490144-40D7A4BA-C826-4DC9-BAA6-1CCDC3726D3C @default.
- Q92490144 P433 Q92490144-AC1B0571-A9B0-46FD-801B-D01999C56A6B @default.
- Q92490144 P478 Q92490144-D995BEFF-0DF3-475A-A03F-D5DFDEBF27A0 @default.
- Q92490144 P577 Q92490144-9589180B-A6D1-432A-AAA3-F64B294F2CF0 @default.
- Q92490144 P698 Q92490144-9CAFFC52-F355-416F-A188-D477806B80E0 @default.
- Q92490144 P921 Q92490144-F08EDE6C-D74B-4745-A4B2-B432F31D6FAF @default.
- Q92490144 P356 S10637-019-00843-Y @default.
- Q92490144 P698 31392549 @default.
- Q92490144 P1433 Q2312231 @default.
- Q92490144 P1476 "Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)" @default.
- Q92490144 P2093 "Akihiro Tamiya" @default.
- Q92490144 P2093 "Daichi Fujimoto" @default.
- Q92490144 P2093 "Hidekazu Suzuki" @default.
- Q92490144 P2093 "Hirotaka Matsumoto" @default.
- Q92490144 P2093 "Junji Uchida" @default.
- Q92490144 P2093 "Katsuya Hirano" @default.
- Q92490144 P2093 "Kazutaka Hosoya" @default.
- Q92490144 P2093 "Masaki Kanazu" @default.
- Q92490144 P2093 "Mitsunori Morita" @default.
- Q92490144 P2093 "Motohiro Tamiya" @default.
- Q92490144 P2093 "Nobuhiko Sawa" @default.
- Q92490144 P2093 "Ryota Kominami" @default.
- Q92490144 P2093 "Satoshi Hara" @default.
- Q92490144 P2093 "Tomonori Hirashima" @default.
- Q92490144 P2093 "Toru Kumagai" @default.
- Q92490144 P2093 "Toshihide Yokoyama" @default.
- Q92490144 P2093 "Yasushi Fukuda" @default.
- Q92490144 P2093 "Yoshihiko Taniguchi" @default.
- Q92490144 P2093 "Yoshinori Kinoshita" @default.
- Q92490144 P304 "1266-1273" @default.
- Q92490144 P31 Q13442814 @default.
- Q92490144 P356 "10.1007/S10637-019-00843-Y" @default.
- Q92490144 P433 "6" @default.
- Q92490144 P478 "37" @default.
- Q92490144 P577 "2019-08-07T00:00:00Z" @default.
- Q92490144 P698 "31392549" @default.
- Q92490144 P921 Q13896859 @default.